Recently Goodwin Procter held a webinar to discuss the impact of the July 21, 2015 Federal Circuit decision in the Amgen v. Sandoz appeal. Hear Elaine Herrmann Blais's analysis of the outcome and thoughts on what is likely to happen next, along with how the decision impacts biosimilars strategy going forward, by viewing the webinar video below, or access the PowerPoint presentation from this webinar here.
Goodwin Procter's Big Molecule Watch has been closely following the developments in this case. To read our observations from the oral argument and our initial analysis of the decision, in addition to reading our updates about other biosimilars news, please click here.
Still have questions? Feel free to email either of the speakers below.